Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinically relevant increases in serum neurofilament light chain and glial fibrillary acidic protein in patients with Susac syndrome.
Plantone D, Sabatelli E, Locci S, Marrodan M, Laakso SM, Mateen FJ, Feresiadou A, Buelens T, Bianco A, Fiol MP, Correale J, Tienari P, Calabresi P, De Stefano N, Iorio R. Plantone D, et al. Among authors: bianco a. Eur J Neurol. 2023 Oct;30(10):3256-3264. doi: 10.1111/ene.15939. Epub 2023 Jun 29. Eur J Neurol. 2023. PMID: 37335505
The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis.
Frisullo G, Mirabella M, Angelucci F, Caggiula M, Morosetti R, Sancricca C, Patanella AK, Nociti V, Iorio R, Bianco A, Tomassini V, Pozzilli C, Tonali PA, Matarese G, Batocchi AP. Frisullo G, et al. Among authors: bianco a. J Neuroimmunol. 2007 Dec;192(1-2):174-83. doi: 10.1016/j.jneuroim.2007.08.008. Epub 2007 Sep 29. J Neuroimmunol. 2007. PMID: 17904647
Glioblastoma in multiple sclerosis: a case report.
Frisullo G, Patanella AK, Nociti V, Cianfoni A, Iorio R, Bianco A, Marti A, Tonali PA, Batocchi AP. Frisullo G, et al. Among authors: bianco a. J Neurooncol. 2009 Aug;94(1):141-4. doi: 10.1007/s11060-009-9804-9. Epub 2009 Feb 13. J Neurooncol. 2009. PMID: 19214706
Type 1 immune response in progressive multiple sclerosis.
Frisullo G, Plantone D, Marti A, Iorio R, Damato V, Nociti V, Patanella AK, Bianco A, Batocchi AP. Frisullo G, et al. Among authors: bianco a. J Neuroimmunol. 2012 Aug 15;249(1-2):112-6. doi: 10.1016/j.jneuroim.2012.04.019. Epub 2012 May 20. J Neuroimmunol. 2012. PMID: 22613700
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group. Prosperini L, et al. Among authors: bianco a. J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26. J Neurol. 2018. PMID: 30259178
Defining the disease course of TNFα blockers-associated Multiple Sclerosis.
Lucchini M, Giuffrè GM, Nociti V, Bianco A, De Fino C, Losavio FA, Presicce G, Calabresi P, Mirabella M. Lucchini M, et al. Among authors: bianco a. J Neuroimmunol. 2021 Apr 15;353:577525. doi: 10.1016/j.jneuroim.2021.577525. Epub 2021 Feb 20. J Neuroimmunol. 2021. PMID: 33647875
2,302 results